for those aged ≥70 and <70 are 70.64% and 85.85%, respectively (P=0.000,1). The three-year overall survival rates of patients whose tumors measured no larger than 2 cm in biggest diameter or larger than 2 cm but no larger than 3 cm are 95.15% and 85.71%, respectively. For those with tumors larger than 3 cm but smaller than 5 cm or larger than 5 cm but smaller than 7 cm, the survival rates are 74.80% and 60.47%, respectively (P<0.000,1). Multivariate analysis reveals that age, gender, vascular vessel invasion, pathologic type, and visceral pleural involvement are significant predictive factors of the overall survival. Conclusion The tumor size and pathologic type are significant independent prognostic factors in stage I NSCLC. The survival rates of patients with adenocarcinoma are higher than those of patients with other types of NSCLC. Female patients and those without a history of smoking have a better outcome. Results suggest that patients with the Ib stage of the disease can benefit from adjuvant chemotherapy.
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